CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Schering-Plough Corporation is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Schering-Plough Corporation
2000 Galloping Hill Road
Phone: (908) 298-4000p:908 298-4000 Kenilworth, NJ  07033  United States Ticker: SGP SGP
This company was Merged or Acquired on 11/3/2009.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Schering-Plough Corporation (Schering-Plough) is a global science-centered healthcare company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough discovers, develops and manufactures pharmaceuticals for prescription, animal health, and consumer markets. The Company operates in three segments: Prescription Pharmaceuticals, Animal Health and Consumer Health Care. The Prescription Pharmaceuticals segment discovers, develops, manufactures and markets human pharmaceutical products. The Animal Health segment discovers, develops, manufactures and markets animal health products. The Consumer Health Care segment develops, manufactures and markets over-the-counter, foot care and sun care products, primarily in the United States.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/200912/31/2008YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
5122 Drugs, drug proprietaries, and druggists' sundries
2844 Perfumes, cosmetics, and other toilet preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer FredHassan 63 4/20/2003 4/20/2003
Chief Financial Officer, Executive Vice President Robert J.Bertolini 47 11/17/2003 11/17/2003
Executive Vice President, General Counsel Thomas J.Sabatino 50 4/15/2004 4/15/2004
12 additional Officers and Directors records available in full report.

Business Names
Business Name
AESCA Pharma GmbH
AESCA Pharma GmbH
Avondale Chemical Co. Ltd.
90 additional Business Names available in full report.

General Information
Number of Employees: 51,000 (As of 12/31/2008)
Outstanding Shares: 1,639,151,392 (As of 9/30/2009)
Shareholders: 33,252
Stock Exchange: NYSE
Federal Tax Id: 221918501
Fax Number: (908) 298-7082


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023